1887

Abstract

Simian–human immunodeficiency virus (SHIV) carrying the envelope from the clade B clinical human immunodeficiency virus type 1 (HIV-1) isolate MNA, designated SHIV MNA, was generated through intracellular homologous recombination. SHIV MNA inherited biological properties from the parental HIV-1, including CCR5 co-receptor preference, resistance to neutralization by the anti-V3 loop mAb KD-247 and loss of resistance in the presence of the CD4-mimic small-molecule YYA-021. SHIV MNA showed productive replication in rhesus macaque PBMCs. Experimental infection of a rhesus macaque with SHIV MNA caused a transient but high titre of plasma viral RNA and a moderate antibody response. Immunoglobulin in the plasma at 24 weeks post-infection was capable of neutralizing SHIV MNA in the presence but not in the absence of YYA-021. SHIV MNA could serve a model for development of novel therapeutic interventions based on CD4-mimic-mediated conversion of envelope protein susceptible to antibody neutralization.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.055590-0
2013-12-01
2020-04-02
Loading full text...

Full text loading...

/deliver/fulltext/jgv/94/12/2710.html?itemId=/content/journal/jgv/10.1099/vir.0.055590-0&mimeType=html&fmt=ahah

References

  1. Davis K. L., Bibollet-Ruche F., Li H., Decker J. M., Kutsch O., Morris L., Salomon A., Pinter A., Hoxie J. A.other authors 2009a; Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 83:1240–1259 [CrossRef][PubMed]
    [Google Scholar]
  2. Davis K. L., Gray E. S., Moore P. L., Decker J. M., Salomon A., Montefiori D. C., Graham B. S., Keefer M. C., Pinter A.other authors 2009b; High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 387:414–426 [CrossRef][PubMed]
    [Google Scholar]
  3. Decker J. M., Bibollet-Ruche F., Wei X., Wang S., Levy D. N., Wang W., Delaporte E., Peeters M., Derdeyn C. A.other authors 2005; Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201:1407–1419 [CrossRef][PubMed]
    [Google Scholar]
  4. Eda Y., Takizawa M., Murakami T., Maeda H., Kimachi K., Yonemura H., Koyanagi S., Shiosaki K., Higuchi H.other authors 2006; Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 80:5552–5562 [CrossRef][PubMed]
    [Google Scholar]
  5. Fujita Y., Otsuki H., Watanabe Y., Yasui M., Kobayashi T., Miura T., Igarashi T. 2013; Generation of a replication-competent chimeric simian-human immunodeficiency virus carrying env from subtype C clinical isolate through intracellular homologous recombination. Virology 436:100–111 [CrossRef][PubMed]
    [Google Scholar]
  6. Gray E. S., Moore P. L., Choge I. A., Decker J. M., Bibollet-Ruche F., Li H., Leseka N., Treurnicht F., Mlisana K.other authors 2007; Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81:6187–6196 [CrossRef][PubMed]
    [Google Scholar]
  7. Igarashi T., Endo Y., Englund G., Sadjadpour R., Matano T., Buckler C., Buckler-White A., Plishka R., Theodore T.other authors 1999; Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. Proc Natl Acad Sci U S A 96:14049–14054 [CrossRef][PubMed]
    [Google Scholar]
  8. Kong L., Sattentau Q. J. 2012; Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J AIDS Clin Res S8:3[PubMed]
    [Google Scholar]
  9. Kwong P. D., Mascola J. R. 2012; Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412–425 [CrossRef][PubMed]
    [Google Scholar]
  10. Landau N. R., Page K. A., Littman D. R. 1991; Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol 65:162–169[PubMed]
    [Google Scholar]
  11. Li M., Gao F., Mascola J. R., Stamatatos L., Polonis V. R., Koutsoukos M., Voss G., Goepfert P., Gilbert P.other authors 2005; Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79:10108–10125 [CrossRef][PubMed]
    [Google Scholar]
  12. Lusso P., Earl P. L., Sironi F., Santoro F., Ripamonti C., Scarlatti G., Longhi R., Berger E. A., Burastero S. E. 2005; Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 79:6957–6968 [CrossRef][PubMed]
    [Google Scholar]
  13. Madani N., Schön A., Princiotto A. M., Lalonde J. M., Courter J. R., Soeta T., Ng D., Wang L., Brower E. T.other authors 2008; Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16:1689–1701 [CrossRef][PubMed]
    [Google Scholar]
  14. Mascola J. R., Stiegler G., VanCott T. C., Katinger H., Carpenter C. B., Hanson C. E., Beary H., Hayes D., Frankel S. S.other authors 2000; Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207–210 [CrossRef][PubMed]
    [Google Scholar]
  15. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. III, Burton D. R., Ho D. D. 1995; Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69:101–109[PubMed]
    [Google Scholar]
  16. Narumi T., Ochiai C., Yoshimura K., Harada S., Tanaka T., Nomura W., Arai H., Ozaki T., Ohashi N.other authors 2010; CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorg Med Chem Lett 20:5853–5858 [CrossRef][PubMed]
    [Google Scholar]
  17. Narumi T., Arai H., Yoshimura K., Harada S., Nomura W., Matsushita S., Tamamura H. 2011; Small molecular CD4 mimics as HIV entry inhibitors. Bioorg Med Chem 19:6735–6742 [CrossRef][PubMed]
    [Google Scholar]
  18. Narumi T., Arai H., Yoshimura K., Harada S., Hirota Y., Ohashi N., Hashimoto C., Nomura W., Matsushita S., Tamamura H. 2013; CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. Bioorg Med Chem 21:2518–2526 [CrossRef][PubMed]
    [Google Scholar]
  19. Nishimura Y., Igarashi T., Haigwood N. L., Sadjadpour R., Donau O. K., Buckler C., Plishka R. J., Buckler-White A., Martin M. A. 2003; Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A 100:15131–15136 [CrossRef][PubMed]
    [Google Scholar]
  20. Nishimura Y., Shingai M., Willey R., Sadjadpour R., Lee W. R., Brown C. R., Brenchley J. M., Buckler-White A., Petros R.other authors 2010; Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol 84:4769–4781 [CrossRef][PubMed]
    [Google Scholar]
  21. Platt E. J., Wehrly K., Kuhmann S. E., Chesebro B., Kabat D. 1998; Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72:2855–2864[PubMed]
    [Google Scholar]
  22. Shibata R., Adachi A. 1992; SIV/HIV recombinants and their use in studying biological properties. AIDS Res Hum Retroviruses 8:403–409 [CrossRef][PubMed]
    [Google Scholar]
  23. Shimizu Y., Okoba M., Yamazaki N., Goto Y., Miura T., Hayami M., Hoshino H., Haga T. 2006; Construction and in vitro characterization of a chimeric simian and human immunodeficiency virus with the RANTES gene. Microbes Infect 8:105–113 [CrossRef][PubMed]
    [Google Scholar]
  24. Shinohara K., Sakai K., Ando S., Ami Y., Yoshino N., Takahashi E., Someya K., Suzaki Y., Nakasone T.other authors 1999; A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. J Gen Virol 80:1231–1240[PubMed]
    [Google Scholar]
  25. Thali M., Moore J. P., Furman C., Charles M., Ho D. D., Robinson J., Sodroski J. 1993; Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67:3978–3988[PubMed]
    [Google Scholar]
  26. von Brunn A., Brand M., Reichhuber C., Morys-Wortmann C., Deinhardt F., Schödel F. 1993; Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine 11:817–824 [CrossRef][PubMed]
    [Google Scholar]
  27. Wei X., Decker J. M., Liu H., Zhang Z., Arani R. B., Kilby J. M., Saag M. S., Wu X., Shaw G. M., Kappes J. C. 2002; Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896–1905 [CrossRef][PubMed]
    [Google Scholar]
  28. Wyatt R., Kwong P. D., Desjardins E., Sweet R. W., Robinson J., Hendrickson W. A., Sodroski J. G. 1998; The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705–711 [CrossRef][PubMed]
    [Google Scholar]
  29. Yamada Y., Ochiai C., Yoshimura K., Tanaka T., Ohashi N., Narumi T., Nomura W., Harada S., Matsushita S., Tamamura H. 2010; CD4 mimics targeting the mechanism of HIV entry. Bioorg Med Chem Lett 20:354–358 [CrossRef][PubMed]
    [Google Scholar]
  30. Yoshimura K., Harada S., Shibata J., Hatada M., Yamada Y., Ochiai C., Tamamura H., Matsushita S. 2010; Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 84:7558–7568 [CrossRef][PubMed]
    [Google Scholar]
  31. Yusa K., Maeda Y., Fujioka A., Monde K., Harada S. 2005; Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J Biol Chem 280:30083–30090 [CrossRef][PubMed]
    [Google Scholar]
  32. Zhao Q., Ma L., Jiang S., Lu H., Liu S., He Y., Strick N., Neamati N., Debnath A. K. 2005; Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339:213–225 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.055590-0
Loading
/content/journal/jgv/10.1099/vir.0.055590-0
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error